All the news Showing 10 of 28 articles from: Pan-genotypic regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources France switches to simplified pangenotypic hepatitis C treatment Keith Alcorn / 05 June 2019 French health authorities have recommended that everyone diagnosed with hepatitis C should be treated with a pangenotypic direct-acting antiviral combination by a general practitioner unless they have severe liver disease, co-infection or kidney ... FDA approves first treatment for all genotypes of hepatitis C in pediatric patients Food & Drug Administration / 02 May 2019 Pangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show Keith Alcorn / 12 April 2019 Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ... New treatment could see NZ eradicate Hepatitis C in next 20 years Newshub / 17 December 2018 8 weeks of Maviret cures 98% of people with hepatitis C and cirrhosis Keith Alcorn / 14 November 2018 An 8-week course of the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C in people with compensated cirrhosis, across a wide range of genotypes, Robert S. Brown of ... The Medicines Patent Pool signs licence with AbbVie to expand access to key hepatitis C treatment, glecaprevir/pibrentasvir Medicines Patent Pool / 12 November 2018 China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection Gilead press release / 30 May 2018 New EASL hepatitis C recommendations emphasise simplicity Liz Highleyman / 23 April 2018 The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment recommendations at the 2018 International Liver Congress this month in Paris. The guidelines are available online in ... 8-week treatment for hepatitis C with Maviret highly effective in people without cirrhosis Keith Alcorn / 13 April 2018 An eight-week course of treatment with the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C infection in people without cirrhosis, results of two real-world studies presented at the ... New affordable hepatitis C combination shows 97% cure rate Keith Alcorn / 12 April 2018 The combination of sofosbuvir and the new NS5A inhibitor ravidasvir cured 97% of people with hepatitis C in a study carried out in Malaysia, and could provide a safe and ... ← First123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive